ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation (ADPT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 70% planned / 30% discretionary
Largest single sale: $8.0M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| OWEN KATEY EINTERZ | Director | Sell | 9,615 | $26.00 | $250.0K | 78,639 −10.9% of holding | |
| ROBINS CHAD M 2 fills | CEO and Chairman | Sell | 278,676 | $24.48 | $6.8M | 2,180,722 −11.3% of holding | |
| HERSHBERG ROBERT 2 fills | Director | Sell | 30,664 | $24.40 | $748.2K | 62,347 −33% of holding | |
| ROBINS CHAD M 2 fills | CEO and Chairman | Sell | 321,324 | $25.08 | $8.1M | 2,183,043 −12.8% of holding | |
| NEUPERT PETER M 3 fills | Director | Sell | 124,690 | $25.15 | $3.1M | 240,315 −34.2% of holding | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell 10b5-1 | 3,000 | $25.00 | $75.0K | 396,989 −0.8% of holding | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell 10b5-1 | 1,299 | $24.00 | $31.2K | 399,989 −0.3% of holding | |
| ROBINS HARLAN S 2 fills | Chief Scientific Officer | Sell 10b5-1 | 492,400 | $21.89 | $10.8M | 1,025,760 −32.4% of holding | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell 10b5-1 | 5,000 | $23.00 | $115.0K | 401,288 −1.2% of holding | |
| LO FRANCIS | Chief People Officer | Sell 10b5-1 | 105,762 | $22.59 | $2.4M | 230,713 −31.4% of holding | |
| ROBINS HARLAN S 2 fills | Chief Scientific Officer | Sell 10b5-1 | 386,240 | $22.01 | $8.5M | 1,166,547 −24.9% of holding | |
| LO FRANCIS | Chief People Officer | Sell 10b5-1 | 44,838 | $22.59 | $1.0M | 230,713 −16.3% of holding | |
| LO FRANCIS 2 fills | Chief People Officer | Sell 10b5-1 | 51,004 | $22.45 | $1.1M | 279,949 −15.4% of holding | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell 10b5-1 | 487 | $22.00 | $10.7K | 406,288 −0.1% of holding | |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell 10b5-1 | 154,768 | $21.14 | $3.3M | 221,278 −41.2% of holding | |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell 10b5-1 | 11,034 | $21.00 | $231.7K | 272,751 −3.9% of holding | |
| GRIFFIN MICHELLE RENEE | Director | Sell 10b5-1 | 52,084 | $20.18 | $1.1M | 15,625 −76.9% of holding | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell 10b5-1 | 5,000 | $20.50 | $102.5K | 406,775 −1.2% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 6,160 | $18.01 | $110.9K | 1,405,898 −0.4% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 100,000 | $17.37 | $1.7M | 1,412,058 −6.6% of holding | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell 10b5-1 | 5,000 | $19.00 | $95.0K | 411,775 −1.2% of holding | |
| LO FRANCIS | Chief People Officer | Sell 10b5-1 | 39,741 | $17.49 | $695.1K | 250,934 −13.7% of holding | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell 10b5-1 | 11,000 | $18.00 | $198.0K | 416,775 −2.6% of holding | |
| PISKEL KYLE | Chief Financial Officer | Sell | 3,115 | $13.04 | $40.6K | 256,725 −1.2% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,037 | $14.23 | $270.9K | 377,802 −4.8% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.02 | $267.2K | 382,132 −4.8% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.74 | $261.9K | 386,470 −4.7% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.13 | $269.3K | 390,808 −4.7% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 30,941 | $14.66 | $453.6K | 395,146 −7.3% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.55 | $277.3K | 399,484 −4.6% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.57 | $277.7K | 403,822 −4.5% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.18 | $270.3K | 408,160 −4.5% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.61 | $278.5K | 412,498 −4.4% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.56 | $277.5K | 416,836 −4.4% of holding | |
| RUBINSTEIN JULIE 2 fills | President and COO | Sell 10b5-1 | 19,060 | $13.15 | $250.6K | 424,512 −4.3% of holding | |
| RUBINSTEIN JULIE 2 fills | President and COO | Sell 10b5-1 | 19,060 | $12.77 | $243.3K | 425,912 −4.3% of holding | |
| RUBINSTEIN JULIE 2 fills | President and COO | Sell 10b5-1 | 19,060 | $13.86 | $264.2K | 431,950 −4.2% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 37,263 | $15.19 | $566.0K | 2,180,518 −1.7% of holding | |
| RUBINSTEIN JULIE 2 fills | President and COO | Sell 10b5-1 | 30,941 | $14.83 | $458.9K | 434,288 −6.7% of holding | |
| LO FRANCIS | Chief People Officer | Sell 10b5-1 | 22,564 | $15.07 | $340.0K | 271,154 −7.7% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 10,000 | $14.85 | $148.5K | 1,512,058 −0.7% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.56 | $258.5K | 438,526 −4.2% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 83,332 | $14.41 | $1.2M | 2,217,781 −3.6% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.33 | $273.1K | 442,864 −4.1% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.60 | $278.3K | 447,202 −4.1% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.45 | $275.4K | 451,540 −4.1% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.45 | $256.4K | 455,878 −4% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $12.63 | $240.7K | 460,216 −4% of holding | |
| RUBINSTEIN JULIE 2 fills | President and COO | Sell 10b5-1 | 19,060 | $13.34 | $254.2K | 480,876 −3.8% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.12 | $269.1K | 468,892 −3.9% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.27 | $272.0K | 473,230 −3.9% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.70 | $261.1K | 477,568 −3.8% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.83 | $263.6K | 481,906 −3.8% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.37 | $254.8K | 486,244 −3.8% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.18 | $251.2K | 490,582 −3.7% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.18 | $251.2K | 494,920 −3.7% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.40 | $255.4K | 499,258 −3.7% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $13.41 | $255.6K | 503,596 −3.6% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $12.96 | $247.0K | 507,934 −3.6% of holding | |
| RUBINSTEIN JULIE 2 fills | President and COO | Sell 10b5-1 | 19,060 | $12.86 | $245.0K | 517,672 −3.6% of holding | |
| ROBINS HARLAN S 2 fills | Chief Scientific Officer | Sell | 470,266 | $13.17 | $6.2M | 1,851,658 −20.3% of holding | |
| ROBINS CHAD M 2 fills | CEO and Chairman | Sell | 470,167 | $13.17 | $6.2M | 2,630,713 −15.2% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell | 122,523 | $13.17 | $1.6M | 520,948 −19% of holding | |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell | 63,103 | $13.17 | $831.1K | 272,751 −18.8% of holding | |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell | 41,338 | $13.17 | $544.4K | 427,775 −8.8% of holding | |
| LO FRANCIS | Chief People Officer | Sell 10b5-1 | 30,593 | $14.08 | $430.7K | 291,374 −9.5% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,060 | $14.08 | $268.4K | 516,610 −3.6% of holding | |
| PISKEL KYLE | Chief Financial Officer | Sell | 18,672 | $13.17 | $245.9K | 259,840 −6.7% of holding | |
| GRIFFIN MICHELLE RENEE | Director | Sell | 15,394 | $13.91 | $214.1K | 15,625 −49.6% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 19,460 | $14.68 | $285.7K | 643,471 −2.9% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 30,941 | $14.79 | $457.6K | 647,809 −4.6% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 30,941 | $15.14 | $468.4K | 652,147 −4.5% of holding | |
| LO FRANCIS | Chief People Officer | Sell | 38,074 | $15.09 | $574.5K | 321,967 −10.6% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 30,941 | $16.00 | $495.1K | 575,235 −5.1% of holding | |
| RUBINSTEIN JULIE | President and COO | Sell 10b5-1 | 30,941 | $16.60 | $513.6K | 579,573 −5.1% of holding | |
| ROBINS CHAD M 2 fills | CEO and Chairman | Sell 10b5-1 | 53,083 | $15.52 | $823.8K | 1,936,627 −2.7% of holding | |
| GRIFFIN MICHELLE RENEE | Director | Sell 10b5-1 | 48,044 | $15.30 | $735.1K | 15,394 −75.7% of holding | |
| RUBINSTEIN JULIE 2 fills | President and COO | Sell 10b5-1 | 30,941 | $15.67 | $484.8K | 590,429 −5% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 14,233 | $16.52 | $235.1K | 1,155,291 −1.2% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 289,024 | $15.82 | $4.6M | 1,987,330 −12.7% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 10,000 | $15.72 | $157.2K | 1,169,524 −0.8% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 182,891 | $15.99 | $2.9M | 2,276,354 −7.4% of holding | |
| PISKEL KYLE | Chief Financial Officer | Sell 10b5-1 | 2,145 | $18.46 | $39.6K | 216,637 −1% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 8,120 | $19.00 | $154.3K | 1,179,524 −0.7% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 124,998 | $18.44 | $2.3M | 2,459,245 −4.8% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 34,668 | $18.60 | $644.8K | 1,187,644 −2.8% of holding | |
| LO FRANCIS | Chief People Officer | Sell 10b5-1 | 79,590 | $17.73 | $1.4M | 315,978 −20.1% of holding | |
| PISKEL KYLE | Chief Financial Officer | Sell 10b5-1 | 4,290 | $18.00 | $77.2K | 216,637 −1.9% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 10,000 | $16.44 | $164.4K | 1,222,312 −0.8% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 124,998 | $15.59 | $1.9M | 2,584,243 −4.6% of holding | |
| LO FRANCIS | Chief People Officer | Sell 10b5-1 | 3,125 | $16.08 | $50.3K | 315,978 −1% of holding | |
| LO FRANCIS 2 fills | Chief People Officer | Sell 10b5-1 | 8,788 | $17.50 | $153.8K | 315,978 −2.7% of holding | |
| LO FRANCIS | Chief People Officer | Sell 10b5-1 | 113,890 | $15.57 | $1.8M | 315,978 −26.5% of holding | |
| HERSHBERG ROBERT | Director | Sell | 22,968 | $16.00 | $367.5K | 46,722 −33% of holding | |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell 10b5-1 | 12,604 | $16.85 | $212.4K | 296,791 −4.1% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 10,000 | $16.61 | $166.1K | 1,232,312 −0.8% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 27,212 | $18.61 | $506.4K | 1,242,312 −2.1% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 124,998 | $18.94 | $2.4M | 2,709,241 −4.4% of holding | |
| PISKEL KYLE | Chief Financial Officer | Sell 10b5-1 | 162,820 | $19.50 | $3.2M | 216,637 −42.9% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 35,736 | $19.68 | $703.3K | 2,834,239 −1.2% of holding | |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell 10b5-1 | 308,477 | $16.91 | $5.2M | 296,791 −51% of holding | |
| BENZENO SHARON | Chief Commercial Ofc Imm Med | Sell 10b5-1 | 297,925 | $16.54 | $4.9M | 296,791 −50.1% of holding | |
| PISKEL KYLE | Chief Financial Officer | Sell | 238 | $14.05 | $3.3K | 269,343 −0.1% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 1,867 | $15.00 | $28.0K | 2,869,975 −0.1% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 1,237 | $14.57 | $18.0K | 2,871,851 −0% of holding | |
| ROBINS CHAD M | CEO and Chairman | Sell 10b5-1 | 86,161 | $14.73 | $1.3M | 2,873,088 −2.9% of holding | |
| ROBINS HARLAN S | Chief Scientific Officer | Sell 10b5-1 | 10,000 | $14.82 | $148.2K | 1,269,524 −0.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.